A clinical trial for the treatment of Chagas disease carried out in Spain with a mostly Latin American population showed that the drug fexinidazole was well tolerated by patients in low doses, although it was not effective in the sustained elimination of the parasite Trypanosoma cruzi, which causes the disease.